Endologix (ELGX) trading halted with news pending
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Barnes & Noble Education (BNED) Enters Definitive Agreement with Immersion (IMMR)
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
Leerink Partners Cuts Price Target on Endologix (ELGX) to $8 Following Analyst Day
November 18, 2016 7:20 AM ESTLeerink Partners maintained a Market Perform rating on Endologix (NASDAQ: ELGX), and cut the price target to $8.00 (from $11.00), following the company's analyst day. The focus of the presentation was around Nellix. There was news on Wednesday that potential approval has been pushed out ~6 months. This comes following a request for additional info from the FDA. Management also updated 2016 revenue... More
Endologix (ELGX) Announces Presentation of Nellix EVAS System Post-Market Study Data in AAA Patients
November 17, 2016 9:33 AM ESTEndologix, Inc. (NASDAQ: ELGX) announced the presentation of two-year clinical data from the Company's EVAS FORWARD - Global Registry, a post-market study that prospectively enrolled patients with abdominal aortic aneurysms ("AAAs") who were treated with the Nellix® EndoVascular Aneurysm Sealing System ("Nellix EVAS System"). Andrew Holden, MD, Associate Professor of Radiology at Auckland City Hospital (Auckland, New Zealand) and one of the principal investigators of the EVAS FORWARD - Global Registry, presented the results at the 2016 VEITH symposium.
The... More
Canaccord Genuity Downgrades Endologix (ELGX) to Hold
November 16, 2016 12:52 PM ESTCanaccord Genuity downgraded Endologix (NASDAQ: ELGX) from Buy to Hold with a price target of $7.50 (from $13.50).
For an analyst ratings summary and ratings history on Endologix click here. For more ratings news on Endologix click here.
Shares of Endologix closed at $9.84 yesterday.
... MoreEndologix (ELGX) will resume trading at 9:50am ET
November 16, 2016 9:22 AM ESTEndologix (NASDAQ: ELGX) will resume trading at 9:50am EST.
... More